These results suggest there is no excess cardiovascular risk with tirzepatide and are consistent with the improvements of numerous surrogate markers of cardiovascular health, including weight reduction, glycemic control with less hypoglycemia, blood pressure reduction, and improvements in the lipid profile
is supported by the University of British Columbia Clinician Investigator Program and a Canadian Institutes of Health Research (CIHR) Canada Graduate ScholarshipMasters Award
Patients should aim for sufficient protein from a variety of sources including lean meats, fish, eggs, dairy products, legumes, and plant-based proteins
Studies have measured outcomes including total body weight change, visceral adipose tissue reduction, fasting glucose normalization, and lipid panel improvements as primary endpoints
Provide a clear treatment plan with short-term and long-term goals
Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer